determining the optimal sequencing of bispecifics and car-t cells in patients with myeloma
Published 1 year ago • 185 plays • Length 3:33Download video MP4
Download video MP3
Similar videos
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
1:42
how to best sequence bispecific antibodies and car-t therapy in multiple myeloma
-
1:55
optimal sequencing of car-t and bispecifics in nhl
-
4:01
determining the optimal sequencing of anti-bcma therapies in multiple myeloma
-
1:27
the value of bispecifics in myeloma & the importance of optimally sequencing immunotherapies
-
6:42
analytical variation: imprecision and bias
-
7:46
pdquest™ software tutorials — optimize spot detection
-
1:57
what is the survival rate for multiple myeloma?
-
2:06
the optimal sequencing of car-t and other immunotherapies in multiple myeloma
-
2:16
the sequencing of novel therapies in myeloma (car-t, bispecifics, antibody-drug conjugates)
-
1:09
optimizing car-t outcomes in dlbcl: possible combination strategies & sequencing of agents
-
1:51
efficacy of odronextamab in r/r dlbcl & determining the optimal sequencing of immune therapies
-
1:14
the car t-cell strategy vs bispecific antibodies
-
1:42
optimal sequencing of immunotherapies to improve outcomes for patients with multiple myeloma
-
4:49
factors to predict the outcomes of patients with r/r myeloma treated with car-t therapy
-
4:49
car-t vs bispecifics in triple-class refractory multiple myeloma: comparing outcomes & sequencing
-
3:38
cite-seq analysis predicts response to car-t therapy and bispecifics in myeloma
-
4:27
the possibility of combining car-t therapy and bispecific antibodies in the treatment of nhl
-
4:35
bispecific antibodies vs car t-cells for r/r multiple myeloma
-
1:45
using frailty to determine car-t eligibility in patients with r/r multiple myeloma
-
1:56
treatment selection & sequencing in patients with relapsed, intolerant, or refractory myeloma
-
12:15
car-t vs bispecific antibodies for lymphoma